Procarbazine and Lomustine in Recurrent Glioblastoma
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The combination therapy of temozolomide and radiation has been established as the standard
therapy for the initial treatment of glioblastoma. However, the prognosis for patients with
recurrent/ refractory glioblastoma is dismal, with a median survival of 3~6 months. There is
no efficient and standard care at the time of recurrence or progression following
temozolomide administration. Recently, many clinicians have reassessed the efficacy of
second-line chemotherapeutic agents such as nitrosoureas for the treatment of
recurrent/refractory glioblastoma. It is very important that the effect of the agent is
sustained and the adverse effect is reduced to preserve the quality of life in recurrent
settings. We have realized that the clinical features of Korean patients are very different
from those of foreign patients. Therefore, it is mandatory to develop the new strategy for
the treatment of Korean patients. We modify the PCV chemotherapy in the dose and
administration schedule of CCNU and procarbazine to reduce the side effect, especially
hematologic problems. The dose of CCNU is reduced to 75mg/m2 and the interval between CCNU
and procarbazine is increased. Moreover, vincristine is excluded because BBB permeability of
vincristine is very poor and the risk of neurotoxicity is high. We introduce the modified PC
chemotherapy regimen for the treatment of recurrent/refractory glioblastoma, which is the
first multicenter trial for glioblastoma patients in Korea.